Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial

(2020) Dinesh Khanna et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis

(2020) Yannick Allanore et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Dinesh Khanna et al.   Lancet Respiratory Medicine

Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma

(2019) Andrea H. L. Low et al.   International Journal of Rheumatic Diseases

Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study

(2019) Muriel Elhai et al.   ANNALS OF THE RHEUMATIC DISEASES

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

(2019) Oliver Distler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti‐topoisomerase I‐positive systemic sclerosis‐associated interstitial lung disease

(2019) Satoshi Ebata et al.   JOURNAL OF DERMATOLOGY

A deeper look at skin scoring in scleroderma – surrogate, outcome, neither or both?

(2019) James R Seibold   RHEUMATOLOGY

Challenges in systemic sclerosis trial design

(2019) Christopher P. Denton   SEMINARS IN ARTHRITIS AND RHEUMATISM

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma

(2018) Keith M. Sullivan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease

(2018) Dinesh Khanna et al.   RHEUMATOLOGY

OUP accepted manuscript

(2018)   RHEUMATOLOGY

Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy

(2018) Timothy M. Pierpont et al.   Frontiers in Oncology

A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease

(2017) Dimitrios Daoussis et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

(2016) Dinesh Khanna et al.   LANCET

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

(2016) Donald P Tashkin et al.   Lancet Respiratory Medicine

Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis

(2015) Silvia L. Bosello et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database

(2014) Britta Maurer et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

(2014) Suzana Jordan et al.   ANNALS OF THE RHEUMATIC DISEASES

Mortality and survival in systemic sclerosis: Systematic review and meta-analysis

(2014) Manuel Rubio-Rivas et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

(2013) Frank van den Hoogen et al.   ANNALS OF THE RHEUMATIC DISEASES

Interstitial Lung Disease in Systemic Sclerosis

(2008) Nicole S. L. Goh et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE